glp-1 lawsuits news claiming Ozempic, other GLP-1s led to blindness become second mass litigation over the drugs Novo Nordisk, maker of the

Novo says an ad campaign crafted by Lilly uses an outdated dose of Novos Wegovy to compare it unfavorably to Lillys Zepbound, accusing the company of withholding information about a higher dose of Wegovy approved by the Food and Drug Administration in March

The document gives a buyer specific numbers to review: accession 2603200134, lot 031826213049, reported purity of 99.703%, and reported content of 5.65mg

Risk factors that may influence the decision to pause treatment include: Being in the dose-escalation phase of GLP-1 therapy Experiencing active gastrointestinal symptoms (nausea, vomiting, bloating) Having known gastroparesis or other conditions affecting gastric emptying Taking concurrent medications that further delay gastric emptying (e.g., opioids) Undergoing procedures with higher aspiration risk (e.g., emergency surgery, airway surgery) If your anaesthetist or surgical team advises temporary cessation based on your individual risk assessment, the timing will depend on the specific medication: Daily injections (such as liraglutide): Typically paused 24 hours before surgery Weekly injections (such as semaglutide, dulaglutide): Often paused with the last dose given at least 7 days before surgery Oral semaglutide (Rybelsus): Usually paused 24 hours before surgery [4] However, these timings may vary according to local NHS Trust protocols and individual clinical assessment

Molecular formula: CHNO Molecular weight: 1024.2 Da CAS number: 121062086 The cyclic structure improves resistance to enzymatic degradation, supporting experimental stability in research applications